Articles related to PEDIATRIC CANCER

Age bias in oncology can lead to younger patients receiving more aggressive treatments with marginal survival benefits, potentially compromising their quality of life.

In a recent phase 3 trial, the addition of brentuximab vedotin to standard chemotherapy not only achieved a notable improvement in 3-year event-free survival rates for pediatric Hodgkin’s lymphoma patients but also maintained a comparable safety profile, underscoring the therapeutic potential of targeted treatments in this population.

In a recent phase 3 trial, a low-dose chemotherapy regimen demonstrated noninferior efficacy to standard-dose regimens in pediatric AML patients, while significantly reducing non-hematologic toxicities, an important consideration in pediatric oncology.

The phase 2 trial provides evidence that dabrafenib combined with trametinib could serve as a more effective and safer first-line treatment option for pediatric low-grade gliomas with BRAF V600 mutations. Evaluate the data to consider how this may influence your treatment protocols.

Discover how base editing via CRISPR-guided cytidine deamination could revolutionize CAR T-cell therapy for T-cell cancers, offering a promising approach to treating relapsed or refractory cases in pediatric patients.

Bridging the Gap: Twinning Programs Improve Pediatric Cancer Survival Rates Across Borders In a world where a few miles can determine the fate of a child with cancer, twinning programs are making a significant difference. These initiatives, which pair hospitals across borders, are helping to bridge the survival gap in pediatric acute leukemia between high-income and lower-income countries. Key Points: “There’s no pediatric centers in many of the mountain west states. If your kid gets cancer in Wyoming, you gotta go to Utah or Colorado or Mayo in Minnesota. But here, there’s really nice evidence that providing the right protocols, training, staff, and more, we could do this in more places and improve outcomes without developing a new drug.” Gwen Nichols, chief medical officer of the Leukemia and Lymphoma Society